Achievement of recommended glucose and blood pressure targets in patients with type 2 diabetes and hypertension in clinical practice – study rationale and protocol of DIALOGUE

Table 1 Overview of documented parameters

Visit	Baseline	FU 6 mo	FU 12 mo	FU 24 mo
Sociodemographics ¹	x
Physical examination ²	x
Cardiovascular concomitant diseases ³	x	x	x	x
Diabetes associated diseases ⁴	x	x	x	x
Available laboratory values⁵	x	x	x	x
Antidiabetic medication⁶	x	x	x	x
Additional current medication	x	x	x	x
Hypoglycaemic events⁸	x	x	x	x
QoL (EuroQoL-5D)	x	x	x	x
Patient reported outcomes (PRO)	x	x	x	x

Legend: 1) age, gender, insurance status, DMP participation, education, employment status, care level 2) weight, height, waist circumference, smoking, alcohol consumption, physical activity 3) coronary heart disease, previous myocardial infarction, previous PCI, previous CABG, previous stroke, heart failure (NYHA) peripheral artery occlusive disease 4) dyslipidemia, amputation, autonomous neuropathy, non- proliferative/proliferative retinopathy, diabetic macular edema, blindness, dialysis other 5) less than six weeks old: lipid values (fasting total cholesterol, fasting LDL, fasting HDL, triglycerides), fasting and post-prandial blood glucose, HbA1c, renal values (serum creatinine, microalbustix albumin, microalbustix creatinine), liver parameters. 6) metformin, sufonylureas, glucosidase inhibitors, glinides, glitazones, DPP-4 inhibitors) 7) ACE inhibitors, ARBs, renin inhibitors, beta blockers, calcium channel blockers, diuretics, other) 8) 12 months before baseline visit and since baseline or last FU, respectively.

ISSN: 1475-2840